University: University of Utah
Projects: Merrimack Pharmaceuticals
Andy Rohrwasser has a PhD in Human Genetics. He is also a cofounder of venture capital funded biotech startup and currently pursuing an MBA through the Executive MBA program at the University of Utah. He is a 2009 finalist of the Kauffman Foundation Fellowship Program.
Andy graduated from the University of Heidelberg (Germany) in chemistry. During his graduate studies (University of Heidelberg) with focus in pharmacology and biochemistry, he trained at the German Institute for High Blood Pressure Research and at the Max-Planck Institute for Biochemistry, Munich. Andy is a recipient of a German Academic Exchange Fellowship. For his dissertation in Human Genetics he was awarded a prestigious Boehringer Ingelheim Fonds Fellowship.
He is the coauthor of several peer reviewed publications, review articles, book chapters, and patents. Andy serves as a reviewer for the American Heart Association and scientific journals including Biotechnology Progress, Journal of Vascular Biology, Hypertension, Genes, BMC Medical Genetics, and Journal of Human Genetics. Andy is a member of the American Society of Human Genetics.
Andy joined UV in 2008. He is interested in biotechnology companies with novel approaches in drug development and targeting, utilizing functional genomics and genetic profiling. He is also interested in healthcare and alternative energies ventures. Upon graduation in May 2009, Andy would like to combine science, strategy, and finance and pursue a career with a Venture Capital or Private equity firm or an investment bank.